Terms: = Leukemia AND PMS2, HNPCC4, 5395, ENSG00000122512, H_DJ0042M02_9, PMSL2, PMS2CL AND Treatment
2657 results:
1. Design, Synthesis, and Anti-Leukemic Evaluation of a Series of Dianilinopyrimidines by Regulating the Ras/Raf/MEK/ERK and STAT3/c-Myc Pathways.
Wang C; Wang B; Mou Y; Liu X; Chen Q; Pu W; Rao Q; Wang C; Song J; Huang Y; Yan L; Huang L; Li Y
Molecules; 2024 Apr; 29(7):. PubMed ID: 38611876
[TBL] [Abstract] [Full Text] [Related]
2. Household income and health-related quality of life in children receiving treatment for acute myeloid leukemia: Potential impact of selection bias in health equity research.
Newman H; Li Y; Huang YV; Elgarten CW; Myers RM; Ruiz J; Zheng DJ; Leahy AB; Aftandilian C; Arnold SD; Bona K; Gramatges MM; Heneghan MB; Maloney KW; Modi AJ; Mody RJ; Morgan E; Rubnitz J; Winick N; Wilkes JJ; Seif AE; Fisher BT; Aplenc R; Getz KD
Cancer Med; 2024 Apr; 13(7):e6966. PubMed ID: 38572962
[TBL] [Abstract] [Full Text] [Related]
3. Opioid Prescribing and Outcomes in Patients With Sickle Cell Disease Post-2016 CDC Guideline.
Kang HA; Wang B; Barner JC; Ataga KI; Mignacca RC; Chang A; Zhang Y
JAMA Intern Med; 2024 May; 184(5):510-518. PubMed ID: 38466269
[TBL] [Abstract] [Full Text] [Related]
4. Neutrophilic Dermatosis of the Hands: A Case Report.
Yaghoobi R; Bagherani N; R Smoller B; Pazyar N
Acta Dermatovenerol Croat; 2023 Dec; 31(3):148-50. PubMed ID: 38439725
[TBL] [Abstract] [Full Text] [Related]
5. Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance.
Claudiani S; Chughtai F; Khan A; Hayden C; Fernando F; Khorashad J; Orovboni V; Scandura G; Innes A; Apperley JF; Milojkovic D
Leukemia; 2024 Apr; 38(4):796-802. PubMed ID: 38424138
[TBL] [Abstract] [Full Text] [Related]
6. Chronic Myeloid leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Shah NP; Bhatia R; Altman JK; Amaya M; Begna KH; Berman E; Chan O; Clements J; Collins RH; Curtin PT; DeAngelo DJ; Drazer M; Maness L; Metheny L; Mohan S; Moore JO; Oehler V; Pratz K; Pusic I; Rose MG; Shomali W; Smith BD; Styler M; Talpaz M; Tanaka TN; Tantravahi S; Thompson J; Tsai S; Vaughn J; Welborn J; Yang DT; Sundar H; Gregory K
J Natl Compr Canc Netw; 2024 Feb; 22(1):43-69. PubMed ID: 38394770
[TBL] [Abstract] [Full Text] [Related]
7. Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera.
Kremyanskaya M; Kuykendall AT; Pemmaraju N; Ritchie EK; Gotlib J; Gerds A; Palmer J; Pettit K; Nath UK; Yacoub A; Molina A; Saks SR; Modi NB; Valone FH; Khanna S; Gupta S; Verstovsek S; Ginzburg YZ; Hoffman R;
N Engl J Med; 2024 Feb; 390(8):723-735. PubMed ID: 38381675
[TBL] [Abstract] [Full Text] [Related]
8. Pancreas-related persisting sequelae in ALL survivors with a history of asparaginase-associated pancreatitis: A part of the ALL-STAR study.
Skipper MT; Birkebæk N; Jensen RB; Rank CU; Tuckuviene R; Wehner PS; Lambine TL; Hørlyck A; Schmiegelow K; Frandsen TL; Andrés-Jensen L; Albertsen BK
Eur J Haematol; 2024 Jun; 112(6):944-956. PubMed ID: 38351310
[TBL] [Abstract] [Full Text] [Related]
9. Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers.
Abaza Y; Winer ES; Murthy GSG; Shallis RM; Matthews AH; Badar T; Geramita EM; Kota VK; Swaroop A; Doukas P; Bradshaw D; Helenowski IB; Liu Y; Zhang H; Im A; Litzow MR; Perl AE; Atallah E; Altman JK
Am J Hematol; 2024 Apr; 99(4):606-614. PubMed ID: 38342997
[TBL] [Abstract] [Full Text] [Related]
10. Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.
Tam CS; Opat S; D'Sa S; Jurczak W; Lee HP; Cull G; Owen RG; Marlton P; Wahlin BE; García-Sanz R; McCarthy H; Mulligan S; Tedeschi A; Castillo JJ; Czyż J; Fernández De Larrea C; Belada D; Libby E; Matous J; Motta M; Siddiqi T; Tani M; Trněný M; Minnema MC; Buske C; Leblond V; Treon SP; Trotman J; Wu B; Yu Y; Shen Z; Chan WY; Schneider J; Allewelt H; Cohen A; Dimopoulos MA
Blood Adv; 2024 Apr; 8(7):1639-1650. PubMed ID: 38315878
[TBL] [Abstract] [Full Text] [Related]
11. Erythroid variant evolving from chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitors: a rare case report.
Lee MH; Song A; Li JY
Diagn Pathol; 2024 Jan; 19(1):21. PubMed ID: 38268039
[TBL] [Abstract] [Full Text] [Related]
12. TIM-3/Galectin-9 interaction and glutamine metabolism in AML cell lines, HL-60 and THP-1.
Shapourian H; Ghanadian M; Eskandari N; Shokouhi A; Demirel GY; Bazhin AV; Ganjalikhani-Hakemi M
BMC Cancer; 2024 Jan; 24(1):125. PubMed ID: 38267906
[TBL] [Abstract] [Full Text] [Related]
13. A Multicenter Study of Needle Size and Safety for Splenic Biopsy.
Kavandi H; Itani M; Strnad B; Martin S; Ebrahimzadeh SA; Lubner MG; Noe-Kim V; Hinshaw JL; Bansal M; Karam AR; Khanna K; Hadied MO; Planz V; Glazer DI; Burgan CM; Galgano S; Brook A; Brook OR
Radiology; 2024 Jan; 310(1):e230453. PubMed ID: 38259204
[TBL] [Abstract] [Full Text] [Related]
14. Real-world Effectiveness of Azacitidine in treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes.
Rajakumaraswamy N; Gandhi M; Wei AH; Sallman DA; Daver NG; Mo S; Iqbal S; Karalliyadda R; Chen M; Wang Y; Vyas P
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):260-268.e2. PubMed ID: 38216397
[TBL] [Abstract] [Full Text] [Related]
15. All-Cause and Cause-Specific Mortality Among Low-Risk Differentiated Thyroid Cancer Survivors in the United States.
Tran TV; Schonfeld SJ; Pasqual E; Haymart MR; Morton LM; Kitahara CM
Thyroid; 2024 Feb; 34(2):215-224. PubMed ID: 38149602
[No Abstract] [Full Text] [Related]
16. MDM2-p53 mediate a miR-181c-3p/LIF axis to regulate low dose-rate radiation-induced DNA damage in human B lymphocytes.
Chen Y; Gong Y; Qin H; Wei S; Wei Y; Yu Y; Lin X; Shuai P; Wang T; Guo C; Wang Q; Li G; Meng L; Yi L
Ecotoxicol Environ Saf; 2024 Jan; 270():115848. PubMed ID: 38134636
[TBL] [Abstract] [Full Text] [Related]
17. Chronic Lymphocytic leukemia Therapy Guided by Measurable Residual Disease.
Munir T; Cairns DA; Bloor A; Allsup D; Cwynarski K; Pettitt A; Paneesha S; Fox CP; Eyre TA; Forconi F; Elmusharaf N; Kennedy B; Gribben J; Pemberton N; Sheehy O; Preston G; Schuh A; Walewska R; Duley L; Howard D; Hockaday A; Jackson S; Greatorex N; Girvan S; Bell S; Brown JM; Webster N; Dalal S; de Tute R; Rawstron A; Patten PEM; Hillmen P;
N Engl J Med; 2024 Jan; 390(4):326-337. PubMed ID: 38078508
[TBL] [Abstract] [Full Text] [Related]
18. Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial.
Al-Sawaf O; Ligtvoet R; Robrecht S; Stumpf J; Fink AM; Tausch E; Schneider C; Boettcher S; Mikusko M; Ritgen M; Schetelig J; von Tresckow J; Vehling-Kaiser U; Gaska T; Wendtner CM; Chapuy B; Fischer K; Kreuzer KA; Stilgenbauer S; Staber P; Niemann C; Hallek M; Eichhorst B
Nat Med; 2024 Jan; 30(1):240-248. PubMed ID: 38071379
[TBL] [Abstract] [Full Text] [Related]
19. Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial.
Zeidan AM; Ando K; Rauzy O; Turgut M; Wang MC; Cairoli R; Hou HA; Kwong YL; Arnan M; Meers S; Pullarkat V; Santini V; Malek K; Kiertsman F; Niolat J; Ramos PM; Menssen HD; Fenaux P; Miyazaki Y; Platzbecker U
Lancet Haematol; 2024 Jan; 11(1):e38-e50. PubMed ID: 38065203
[TBL] [Abstract] [Full Text] [Related]
20. Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia.
Lane AA; Garcia JS; Raulston EG; Garzon JL; Galinsky I; Baxter EW; Leonard R; DeAngelo DJ; Luskin MR; Reilly CR; Stahl M; Stone RM; Vedula RS; Wadleigh MM; Winer ES; Mughal T; Brooks C; Gupta IV; Stevenson KE; Neuberg DS; Ren S; Keating J; Konopleva M; Stein A; Pemmaraju N
Blood Adv; 2024 Feb; 8(3):591-602. PubMed ID: 38052038
[TBL] [Abstract] [Full Text] [Related]
[Next]
